| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4a091bb1d2ee96e35d165d3249665e39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_902c376baaa63319929e78fbed53be48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca7b98c0c36c344c903b499a949b3298 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6835
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3069 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K6-00 |
| filingDate |
2004-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddd1bf1c08a11784e4d68eb38bff816e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8887c766fa87c970eb00d1c76dcf3792 |
| publicationDate |
2004-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2004078137-A2 |
| titleOfInvention |
Antitumor agents comprising a targeting portion and an immune response triggering portion |
| abstract |
The present invention provides an antitumor agent comprising a targeting portion and an immune response triggering portion. The targeting portion may be an antibody fragment or a tumor vasculature binding peptide. The immune response triggering portion may be an Fc fragment of immunoglobulin G (IgG), a fragment of the Fc fragment of IgG that exhibits the same biological function as the Fc region, or the extracellular domain of foreign major histocompatability complex (MHC). The antitumor agent is useful for inhibiting tumor growth, inhibiting tumor angiogenesis and treating diseases associated with neovascularization. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8875813-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016527265-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10208097-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3029071-A4 |
| priorityDate |
2003-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |